Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V2 Phase 3 Results
Key Takeaways TRuE-V2 confirmed facial repigmentation superiority of ruxolitinib 1.5% cream versus vehicle at ~24 weeks, mirroring TRuE-V1. Continued treatment […]
facial repigmentation
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V1 Phase 3 Results
Key Takeaways In TRuE-V1, topical ruxolitinib 1.5% cream showed clinically meaningful facial repigmentation versus vehicle by week 24, with continued
NB-UVB 311 nm vs PUVA in Vitiligo: Comparative Efficacy and Safety
Key Takeaways NB-UVB achieves comparable or superior facial repigmentation versus PUVA in multiple comparative studies, with fewer systemic adverse effects.
NB-UVB 311 nm for Vitiligo: Cohort Evidence, Protocols, Predictors, and Safety
Key Takeaways NB-UVB (311–313 nm) consistently induces clinically meaningful repigmentation across multiple cohorts; face responds best, acral sites worst. Typical regimens